- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:30 | Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? | 1 | Benzinga.com | ||
| 16:26 | OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients | 2 | FierceBiotech | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 15:06 | OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial | 2 | Seeking Alpha | ||
| 15:06 | Pre-market Movers: Safe & Green Holdings, OS Therapies, Vision Marine Technologies, Giftify, Millennium Group International | 294 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Safe & Green Holdings Corp. (SGBX) is up over 155%... ► Artikel lesen | |
| 14:22 | OS Therapies-Aktie steigt nach Erfolg in Phase-2b-Studie stark an | 2 | Investing.com Deutsch | ||
| 14:18 | OS Therapies stock soars on Phase 2b trial success | 2 | Investing.com | ||
| Di | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| Mo | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 03.01. | OS Therapies Inc - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 30.12.24 | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 24.12.24 | OS Therapies prices $6M private placement | 1 | Seeking Alpha | ||
| 18.11.24 | OS Therapies reports Q3 results | 2 | Seeking Alpha | ||
| 15.11.24 | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 15.11.24 | OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update | 226 | Business Wire | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported... ► Artikel lesen | |
| 15.11.24 | OS Therapies Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.24 | OS Therapies Inc - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| 12.11.24 | OS Therapies files to sell $15M in common stock for holders | 1 | Seeking Alpha | ||
| 12.11.24 | OS Therapies Inc - S-1, General form for registration of securities | - | SEC Filings | ||
| 28.10.24 | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 28.10.24 | OS Therapies expands board with biopharma veterans | 3 | Investing.com |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,175 | -0,15 % | Biotech Report: Evotec und Qiagen im Plus | (shareribs.com) Frankfurt / New York 09.01.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Hier konnten unter anderem Evotec und Qiagen zulegen. In den USA fand aufgrund eines... ► Artikel lesen | |
| TEMPUS AI | 34,920 | +9,73 % | Tempus AI (TEM) Launches AI-Powered Whole-Genome Sequencing Test to Transform Precision Medicine | ||
| ADMA BIOLOGICS | 16,710 | +2,39 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| NUVALENT | 77,44 | +7,08 % | Nuvalent, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 18,200 | +9,31 % | Why Summit Therapeutics Rocketed 584% in 2024 | ||
| RECURSION PHARMACEUTICALS | 6,420 | +1,42 % | CEO von Recursion Pharmaceuticals verkauft Aktien im Wert von 287.200 US-Dollar | ||
| VERA THERAPEUTICS | 33,880 | -2,21 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
| EVOTEC | 7,955 | +1,34 % | Evotec Aktie: Markt bleibt ruhig | Die Evotec SE verzeichnete am Handelstag einen überraschend positiven Verlauf an der Börse. Nach einem verhaltenen Start bei 8,73 EUR entwickelte sich der Kurs im Tagesverlauf dynamisch nach oben und... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 69,59 | +5,50 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities | Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide... ► Artikel lesen | |
| KEROS THERAPEUTICS | 10,410 | -16,85 % | Keros pulls study of Winrevair rival after safety signal | ||
| HARMONY BIOSCIENCES | 36,930 | +1,46 % | Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts | PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,540 | +3,67 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 27,870 | +3,15 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| CG ONCOLOGY | 29,610 | +5,98 % | CG Oncology-Direktor Leonard Post verkauft Aktien im Wert von 29.660 US-Dollar | ||
| BIONTECH | 110,50 | +1,47 % | Erhebliches Aufwärtspotenzial: "Kaufen!" - Warum jetzt auch diese Analysten auf BioNTech setzen! | © Foto: Schoening - picture allianceDie Aktie von BioNTech liebäugelt mit einem wichtigen charttechnischen Ausbruch. Schützenhilfe könnte sie von einer weiteren Kaufempfehlung erhalten.Die Aktie des... ► Artikel lesen |
OS THERAPIES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,300 Euro und damit +3,12 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.
